Literature DB >> 15261842

Androgens and the ageing male.

Ronald S Swerdloff1, Christina Wang.   

Abstract

Serum testosterone levels peak in early adulthood in men and fall progressively with age. Since sex hormone binding globulin increases with age, the unbound forms of testosterone (free and bioavailable testosterone) fall more steeply than total testosterone levels. Serum testosterone levels below the normal range for young healthy adult males provide chemical evidence of androgen deficiency independent of the age of the patient. When accompanied by signs or symptoms that are compatible with androgen deficiency, treatment with testosterone should be considered in older men without evidence of prostate or breast cancer. While such therapy for younger hypogonadal men has shown benefit on libido, mood, muscle mass, muscle strength, bone mineral density and haematocrit, similar benefits in older men have not been as adequately assessed. While there is no convincing evidence that testosterone treatment in older men will increase the risk of cardiovascular or prostate cancer, long-term, well-controlled studies are lacking and needed. Treatment options for older men include injectable, transdermal and transbuccal testosterone preparations. Copyright 2004 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261842     DOI: 10.1016/j.beem.2004.03.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  18 in total

1.  Hormone therapy for the ageing. Despite the negative results of recent trials, hormone replacement therapy retains enticing promises for the elderly.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2004-10       Impact factor: 8.807

2.  Testosterone restores respiratory long term facilitation in old male rats by an aromatase-dependent mechanism.

Authors:  N R Nelson; I M Bird; M Behan
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

3.  Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010.

Authors:  Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Holly M Holmes; Mukaila A Raji; Abraham Morgentaler; Bret T Howrey; Yu-Li Lin; Kenneth J Ottenbacher
Journal:  Public Health Rep       Date:  2015 Mar-Apr       Impact factor: 2.792

Review 4.  Androgens, aging, and Alzheimer's disease.

Authors:  Christian J Pike; Emily R Rosario; Thuy-Vi V Nguyen
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 5.  Estrogen and testosterone therapies in multiple sclerosis.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Prog Brain Res       Date:  2009       Impact factor: 2.453

6.  Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy.

Authors:  Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin
Journal:  Ann Pharmacother       Date:  2014-07-02       Impact factor: 3.154

7.  Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Monika Eichholzer; Aline Barbir; Shehzad Basaria; Adrian S Dobs; Manning Feinleib; Eliseo Guallar; Andy Menke; William G Nelson; Nader Rifai; Elizabeth A Platz; Sabine Rohrmann
Journal:  Aging Male       Date:  2012-07-23       Impact factor: 5.892

8.  Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells.

Authors:  J Y Chung; H Chen; A Midzak; A L Burnett; V Papadopoulos; B R Zirkin
Journal:  Endocrinology       Date:  2013-03-22       Impact factor: 4.736

9.  Urinary Amine Metabolomics Characterization with Custom 12-Plex Isobaric DiLeu Labeling.

Authors:  Pingli Wei; Ling Hao; Samuel Thomas; Amanda Rae Buchberger; Laura Steinke; Paul C Marker; William A Ricke; Lingjun Li
Journal:  J Am Soc Mass Spectrom       Date:  2020-08-04       Impact factor: 3.109

Review 10.  Leydig cells: From stem cells to aging.

Authors:  Haolin Chen; Ren-Shan Ge; Barry R Zirkin
Journal:  Mol Cell Endocrinol       Date:  2009-02-07       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.